AbVacc - JOURNAL

Vaccine

Evidence of Neutralizing and Non-Neutralizing Anti-Glucosaminidase Antibodies in Patients With S. aureus Osteomyelitis and Their Association With Clinical Outcome Following Surgery in a Clinical Pilot.

- Front Cell Infect Microbiol

2023 Aug 18
12:876898

Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.

- MAbs.

2023 Jan-Dec
14(1):2002236.

Strain Neutralizing and Protective Monoclonal Antibodies against EEEV or WEEV.

- Viruses..

2021 Nov 5
13(11):2231 doi: 10.3390/v13112231

Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.

- Proc Natl Acad Sci U S A.

2021 Sep 14
118(37):e2100104118.

Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody.

- Proc Natl Acad Sci U S A.

2021 Mar 16
118(11):e2023332118.

Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.

- mBio.

2021 Jan 12
12(1):e01438-20.

Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.

- PLoS Pathog.

2019 Nov 7
15(11):e1008061

Potent Neutralization of Staphylococcal Enterotoxin B In Vivo by Antibodies that Block Binding to the T-Cell Receptor.

- J Mol Biol.

2019 Mar 27

Structural basis of broad ebolavirus neutralization by a human survivor antibody.

- Nat Struct Mol Biol.

2019 Mar
26(3):204-212.

Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates.

- -Nat Commun.

2019 Jan 10
10(1):105..

Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop.

- Nat Commun.

2018 Sep 26
9(1):3934.

Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.

- Cell.

2017 May 18
169(5):891-904.e15.

Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection.

- Hepatology.

2016 Dec
64(6):1922-1933.

A "Trojan horse" bispecific antibody strategy for broad protection against ebolaviruses.

- Science.

2016 Sep 8
pii: aag3267.

Antibody

Wall Teichoic Acids Facilitate the Release of Toxins from the Surface of Staphylococcus aureus.

- Microbiol Spectr.

2023 Aug 31
10(4):e0101122.

Hyperimmune Targeting Staphylococcal Toxins Effectively Protect Against USA 300 MRSA Infection in Mouse Bacteremia and Pneumonia Models.

- Front Immunol.

2023 May 17
10(4):e0101122.

Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort.

- Sci Transl Med.

2021 Oct 26
eabj7521. doi: 10.1126/scitranslmed.abj7521.

IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus.

- Front Immunol.

2021 Mar 10
10(4):e0101122.

Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus Macaques.

- Front Immunol.

2021 Feb 25
12:621754.

Efficacy of Active Immunization with Attenuated Alpha-Hemolysin and Panton-Valentine Leukocidin in a Rabbit Model of Staphylococcus aureus Necrotizing Pneumonia.

- J Infect Dis.

2019 Aug 26

Rational Design of Toxoid Vaccine Candidates for Staphylococcus aureus Leukocidin AB (LukAB).

- Toxins (Basel).

2019 Jun 14
11(6).

TBA225, a fusion toxoid vaccine for protection and broad neutralization of staphylococcal superantigens.

- Sci Rep.

2019 Mar 1
9(1):3279.

Viral Hemorrhagic Fever Immunotherapeutic Consortium.

- Cell. 2018

2023 Aug 9
174(4):938-952.e13.

The safety and immunogenicity of a parenterally administered structure-based rationally modified recombinant Staphylococcal enterotoxin B protein vaccine, STEBVax.

- Clin Vaccine Immunol.

2016 Oct 5
pii: CVI.00399-16.